Associate Director, Clinical Biomarker Neuro-Immunology, Late Stage Translational Development at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Recognized expertise in translational biomarkers in neuroimmunology
Experience in late-stage drug development activities related to clinical trial initiation, maintenance, and completion
Strong verbal and written communication skills
Experience in interacting with CROs and TLs to manage projects and timelines
Proven scientific/leadership expertise (working in teams, mentoring people, managing projects)
Accountable for timelines and deliverables
Prioritizes risks and implements contingency plans
Communicates regularly and prepares presentations

Responsibilities

Designs and implements program-specific late development biomarker/translational plans
Creates clinical protocols, SAPs, SOWs, lab manuals, and interfaces with CROs for service execution
Determines appropriate assays and vendors for clinical biomarkers and manages outsourcing
Manages clinical biomarker data delivery and analysis, working with internal functions and CROs
Prepares and delivers internal and external translational/biomarker presentations
Maintains timelines for biomarker data related to publication, collaborating with Medical Communications and Publication teams
Keeps up-to-date on relevant scientific/technical literature and applies external knowledge to internal research programs
Works with TM laboratory scientists and academic TLs to address nonclinical translational questions
Participates in post-hoc biomarker analysis and publication efforts
Supports regulatory submissions and interactions as needed

Skills

neuroimmunology

translational biomarkers

clinical protocols

SAPs

SOWs

lab manuals

CRO management

biomarker assays

data analysis

scientific presentations

project management

regulatory submissions

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free